GLP1R and diabetes mellitus: This study will use all the available IPD and aggregate-level trial data and data from a diabetes register to estimate the effectiveness of SGLT2 inhibitor, GLP1 receptor analogue and DPP4 inhibitors for patients in routine care settings.